Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.
Phase 2
Completed
- Conditions
- Dyslipidemia
- Registration Number
- NCT00326326
- Lead Sponsor
- Pfizer
- Brief Summary
To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 84
Inclusion Criteria
- HDL-C < or = 45 mg/dL for men and < or = 55 mg/dL for women
- Triglycerides between 150-500 mg/dL
- Fasting Plasma Glucose 140-240 mg/dL
Read More
Exclusion Criteria
- Known cardiovascular, carotid, or peripheral vascular disease
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method HDL-C Safety and Efficacy
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇺🇸Milwaukee, Wisconsin, United States